Alopecia totalis is a form of autoimmune hair loss that causes complete or near-complete loss of hair on the scalp. It’s a more extensive subtype of alopecia areata, the common condition where hair falls out in small, round patches. While most people with alopecia areata lose hair in isolated spots that often regrow within a year, alopecia totalis represents a progression to total scalp hair loss, with hair on the rest of the body typically preserved.
How It Differs From Other Forms of Alopecia
Alopecia areata exists on a spectrum. The most common form, sometimes called alopecia areata focalis, produces smooth, round bald patches on the scalp. Alopecia totalis is what happens when those patches spread until the entire scalp is bare. If hair loss continues beyond the scalp to include eyebrows, eyelashes, and all body hair, the condition is classified as alopecia universalis.
In alopecia totalis, the hair follicles themselves are not destroyed. If you look closely at the scalp, the tiny openings where hairs grow (follicular orifices) are still visible. This is an important distinction from scarring alopecia, where the follicles are permanently damaged and those openings disappear. The scalp in alopecia totalis generally looks smooth, without significant redness or flaking.
What Causes It
Alopecia totalis is an autoimmune condition. The immune system, specifically a type of white blood cell called a CD8+ T cell, mistakenly attacks hair follicles. Hair follicles normally have a kind of built-in invisibility cloak that hides them from immune surveillance. When this protection breaks down, the immune system spots proteins in the hair follicle that it misidentifies as threats, triggering an inflammatory attack. Skin biopsies from affected areas show clusters of immune cells swarming around the base of hair follicles.
What causes this immune protection to collapse isn’t fully understood, but it involves a chain reaction of signaling errors: inflammatory molecules ramp up, local immune-suppressing signals weaken, and the follicle becomes exposed. Genetics, stress, and other autoimmune conditions all appear to play a role in tipping this balance.
Who Gets It and How Common Is It
Alopecia areata as a whole affects roughly 0.2% of the US population. Among those diagnosed, an estimated 4.5% to 36.1% eventually progress to alopecia totalis or alopecia universalis. That’s a wide range, reflecting the unpredictable nature of the disease. Some people develop totalis rapidly, while others have patchy hair loss for years before it spreads. It can occur at any age, including in children.
Signs Beyond Hair Loss
Nail changes are surprisingly common. Roughly 30% of people with alopecia areata have some form of nail involvement, and in some clinical studies the number runs much higher. The most frequent nail abnormalities are pitting (tiny dents in the nail surface, found in over half of patients in one study), horizontal or vertical ridging, and notching at the nail tips. Brittle nails are more common in women. These nail changes aren’t dangerous, but they’re a useful diagnostic clue and can be cosmetically bothersome.
How It’s Diagnosed
Diagnosis is usually straightforward for a dermatologist based on appearance alone. The complete, smooth scalp hair loss with preserved follicular openings is distinctive. When there’s any uncertainty, a tool called a trichoscope (essentially a magnifying device for examining the scalp) can reveal telltale patterns: yellow dots where follicles have filled with oil and skin debris, black dots where broken hair shafts sit just at the skin surface, and tapered “exclamation point” hairs that are thicker at the tip and thinner at the root. Yellow dots and short, fine regrowing hairs are the most sensitive indicators, while black dots and tapered hairs are the most specific to this condition, helping rule out other causes of hair loss like fungal infections or hair-pulling disorders.
Chances of Hair Regrowth
The prognosis for alopecia totalis is less favorable than for patchy alopecia areata. The widely cited statistic is that fewer than 10% of people with alopecia totalis experience full spontaneous regrowth. However, a longitudinal study following patients for more than 10 years found a somewhat more encouraging picture: about 21% of people with alopecia totalis achieved complete hair regrowth over time. The researchers suggested that long-term outcomes may be better than the commonly reported numbers, though unpredictable. Hair can regrow years or even decades after loss, then fall out again. This uncertainty is one of the most challenging aspects of living with the condition.
Treatment Options
For people with limited patchy hair loss, corticosteroid creams and minoxidil (a topical growth-stimulating medication) are common starting points. But alopecia totalis involves extensive loss, and these topical treatments alone rarely produce meaningful regrowth across an entire scalp.
Contact immunotherapy is one established approach for widespread alopecia areata. A chemical is applied to the scalp to deliberately cause a mild allergic reaction, which redirects the immune system’s attention away from hair follicles. Success rates for regrowing hair range from 17% to 75%, a spread that reflects how differently people respond.
The most significant recent development has been JAK inhibitors, a class of oral medications that block the specific immune signaling pathways driving the follicle attack. Three are now FDA-approved for severe alopecia areata:
- Baricitinib (approved 2022): In clinical trials, 35 to 40% of patients achieved at least 80% scalp hair coverage by week 36.
- Ritlecitinib (approved 2023, for ages 12 and up): 32% reached at least 80% scalp hair coverage by week 24.
- Deuruxolitinib (approved 2024): 41% achieved at least 80% scalp hair coverage by week 24.
These numbers represent a real shift for people with extensive hair loss, though they also mean that a substantial portion of patients don’t achieve significant regrowth even with the newest medications. JAK inhibitors also require ongoing use; hair loss can return if the medication is stopped.
Emotional and Psychological Effects
Losing all your hair affects far more than appearance. In one study of adults with alopecia areata, 77.6% reported reduced quality of life. Nearly two-thirds showed signs of depression or anxiety, and about 71% of those without any other chronic illness still had some degree of depression or anxiety on standardized screening tools. Stress levels, measured by a validated scale, were significantly above population norms. About 12.8% of adult participants screened positive for suicide risk.
Children appear to cope somewhat differently. Only about 6% of children in the same study showed depressive symptoms, though quality of life was still affected in over three-quarters of them. The social dimension of hair loss, particularly for adolescents and women, can be profound, affecting relationships, work, and daily confidence. Many people with alopecia totalis find that connecting with support communities and working with a therapist experienced in chronic illness makes a meaningful difference alongside any medical treatment they pursue.